At the news
? NEUTRALIMPACT 4/10 DEF 14A filed Nov 5, 2026 at 16:30 ET
NRX Pharmaceuticals filed its definitive proxy statement for the 2026 annual meeting, seeking to elect Dennis McBride as the sole Class II director and ratify Weinberg & Company as auditors. The filing is routine but occurs alongside a DEFA14A filed the same day indicating a contested election, adding governance uncertainty.
- Annual meeting scheduled for December 17, 2026, virtual-only format.
- Only one director nominee: Dennis McBride for Class II.
- Board has 5 directors, all male, all White; classified board with staggered three-year terms.
- CEO Jonathan Javitt also serves as Chairman (combined role).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access